Money

Christmas Day Operating Hours: What's Open and Closed?

As families gather to celebrate Christmas on December 25, understanding which services and businesses are operational is crucial for planning. This guide provides a comprehensive overview of establishments that will be closed or open with modified hours during the holiday.

Navigating the Holiday: Essential Business Hours on Christmas Day

Widespread Closures: Federal, Financial, and Major Retail Sectors Halt Operations

On Thursday, December 25th, the nation will observe Christmas Day with a significant number of closures. Most federal and financial entities will cease operations for the holiday. This includes all banking institutions, post offices, and the major stock exchanges, NYSE and Nasdaq, which will not conduct trading. Additionally, prominent shipping and logistics companies, such as United Parcel Service Inc. (NYSE: UPS) and FedEx Corp. (NYSE: FDX), will suspend their regular pickup and delivery services, impacting package flow.

Retail Giants Observe the Holiday: Stores Closed Nationwide

Major retail corporations are also prioritizing their employees' holiday by closing their doors. Consumers will find that large chains like Walmart Inc. (NYSE: WMT), Target Corp. (NYSE: TGT), Costco Wholesale Corp. (NASDAQ: COST), Macy's Inc. (NYSE: M), and Kohl's Corp. (NYSE: KSS) will not be open for business on Christmas Day. This widespread closure among retailers emphasizes the holiday's importance as a time for rest and celebration for many workers.

Essential Services Remain Available: Pharmacies and Convenience Stores Adjust Hours

While many businesses will be closed, certain essential services will remain accessible to the public, albeit with altered schedules. Selected pharmacy chains, including CVS Health Corp. (NYSE: CVS) and Walgreens, plan to operate on Christmas Day. However, customers are advised to confirm local store hours in advance, as pharmacy counters might be closed even if the retail section is open. Convenience stores like 7-Eleven will also welcome customers, typically with adjusted operating times to accommodate the holiday.

Resumption of Normal Operations: Post-Holiday Business Outlook

Following the Christmas holiday, regular business activities are set to resume. Financial markets, banks, and post offices will reopen their doors on Friday, November 28th, returning to their standard operating hours. This quick return to normal ensures that economic and public services experience minimal disruption beyond the holiday itself, allowing for a swift transition back to routine.

Home Equity Line of Credit (HELOC) Rates Drop: What You Need to Know

As of late 2025, the financial landscape for homeowners seeking to leverage their property wealth is becoming increasingly favorable. Average rates for Home Equity Lines of Credit (HELOCs) have reached unprecedented lows, dipping below 7% in some cases. This development offers a compelling avenue for those looking to tap into their home's value without disturbing their existing, potentially low-interest, primary mortgages.

Unlock Your Home's Potential: Navigate Lower HELOC Rates and Smart Borrowing

The Current Landscape of HELOC Rates and Eligibility Requirements

The national average for Home Equity Line of Credit (HELOC) interest rates is currently experiencing a significant downturn, reaching new low points for 2025. This trend presents a valuable opportunity for homeowners. Eligibility for the most competitive rates is typically reserved for individuals with strong credit profiles. Specifically, data from financial analytics firms indicates that the average HELOC rate in December stands at 7.44% for applicants possessing a minimum credit score of 780 and a combined loan-to-value (CLTV) ratio not exceeding 70%. These criteria underscore the importance of maintaining excellent credit health to secure the best possible borrowing terms.

The Strategic Advantage of HELOCs in Today's Market

Homeowners across the nation are currently sitting on a record amount of equity, with collective home values reaching nearly $36 trillion by the second quarter of 2025, as reported by the Federal Reserve. This represents an all-time high in accumulated home wealth. Given that many homeowners benefit from historically low primary mortgage rates, often in the 3% to 5% range, refinancing or selling their homes might not be the most financially prudent decision. In this scenario, a HELOC emerges as an exceptional alternative. It allows property owners to access the capital tied up in their homes on an as-needed basis, providing financial flexibility without sacrificing the benefits of their existing low-rate mortgages.

Understanding the Mechanics of HELOC Interest Rates

HELOC interest rates operate differently from those of primary mortgages. They are typically structured as adjustable rates, determined by an index rate—frequently the prime rate—plus an additional margin set by the lender. For instance, if the prime rate is 6.75% and a lender applies a margin of 0.75%, the resulting HELOC rate would be 7.50%. Lenders possess considerable discretion in setting these margins, making it crucial for consumers to meticulously compare offers. Factors influencing individual rates include credit scores, existing debt levels, and the loan-to-value ratio of the credit line. It is also important to note that many HELOCs feature attractive introductory rates for an initial period, which then adjust to a variable rate that could be substantially higher.

Maximizing Your HELOC: Best Practices and Lender Selection

To secure the most advantageous HELOC, it is imperative to engage in thorough comparison shopping among various lenders. The most favorable HELOC providers often distinguish themselves by offering minimal fees, the option to convert to a fixed rate, and generous credit limits. A HELOC provides unparalleled flexibility, allowing borrowers to draw funds as needed, repay them, and redraw again, up to their approved limit, only paying interest on the amount borrowed. For example, one credit union is currently offering an introductory rate of 5.99% for 12 months on lines up to $500,000, which then transitions to a variable rate of 7.25%. When evaluating offers, it is essential to consider not only the initial and variable rates but also all associated fees, repayment terms, and the minimum initial draw requirement. The ultimate rate secured will depend significantly on one's creditworthiness and diligence in selecting a lender.

Strategic Uses and Potential Pitfalls of HELOCs

For homeowners enjoying low primary mortgage rates and substantial home equity, now is an opportune moment to consider a HELOC. This financial tool enables access to cash for a variety of purposes, including home improvements, necessary repairs, or even discretionary spending like vacations, provided there is a disciplined repayment plan in place. It is important to approach discretionary spending with caution, as accumulating long-term debt for non-essential items might not be advisable. While a HELOC can function over an extended period—potentially up to 30 years—borrowers should be aware that variable rates can cause monthly payments to fluctuate and increase. For instance, drawing $50,000 at a 7.50% interest rate could result in a monthly payment of approximately $313 during the 10-year draw period. However, this payment can rise during the subsequent 20-year repayment phase. HELOCs are most effectively utilized when the borrowed funds are repaid relatively quickly, minimizing overall interest accumulation.

See More

Biohaven Shares Plummet After Depression Drug Fails Phase 2 Trial

Biohaven Ltd. recently faced a considerable setback in its drug development efforts, leading to a notable decline in its stock value. This report details the trial's outcome, the company's response, and the broader implications for its future direction in the biopharmaceutical landscape.

Biohaven's Strategic Pivot: From Psychiatric Setback to New Therapeutic Horizons

Unfavorable Results in Depression Drug Trial

Shares of Biohaven Ltd. (BHVN) saw a sharp decline in after-hours trading, falling by 16.19% to $9.06. This downturn occurred after the company disclosed that its investigational drug, BHV-7000, intended for major depressive disorder, did not meet the primary efficacy goal in its Phase 2 clinical study. The study, which spanned six weeks, aimed to assess the drug's effectiveness in reducing depressive symptoms, utilizing the Montgomery Åsberg Depression Rating Scale for measurement. Despite the overall trial outcome, Biohaven noted some positive trends within specific subgroups of patients who presented with more severe depression at the trial's outset, observing favorable indicators on both primary and secondary outcome measures for BHV-7000.

Consistent Safety Profile Observed

Throughout the clinical investigation, BHV-7000 demonstrated a favorable safety profile, with most reported adverse events being mild in nature. Analysis of adverse event data revealed that headaches were experienced by 10.7% of patients receiving BHV-7000, compared to 9.9% in the placebo group. Nausea was reported by 4.2% of patients in the BHV-7000 arm, while 5.6% of placebo recipients experienced this side effect. These findings suggest that the drug was generally well-tolerated by participants in the study.

Re-evaluating Research and Development Focus

Following the disappointing Phase 2 trial results for BHV-7000, Dr. Ahmed Tahseen, Biohaven's Development Lead for Depression, stated that the findings do not support the drug's efficacy across a broad population of individuals with depression. In light of this, Biohaven is contemplating a significant shift in its research and development strategy. The company is considering discontinuing its psychiatric drug trials and reallocating resources towards other promising therapeutic areas. The strategic redirection for 2026 is expected to prioritize immunology, obesity, and epilepsy. Further insights and updates on its clinical programs, including data from its extracellular degrader initiatives and a Phase 2b obesity study, are anticipated to be shared by management at the upcoming J.P. Morgan Healthcare Conference in January.

Market Performance and Outlook

Biohaven's stock closed the regular trading session at $10.81, showing a modest increase of 2.95% before the after-hours decline. The company currently holds a relative strength index (RSI) of 50.35 and a market capitalization of $1.43 billion. Over the past year, the stock has experienced a substantial drop of 70.32%, indicating prolonged weakness. Its 52-week trading range spans from $7.48 to $44.28, with the current price hovering approximately 9.1% above its 52-week low. This proximity to its historical lows suggests a lack of robust buying interest and highlights the potential for further price volatility. An analysis of Benzinga's Edge Stock Rankings reveals a negative price trend for BHVN across all timeframes, underscoring the challenges the company faces in regaining investor confidence and market momentum.

See More